Multipotent Mesenchymal Stromal Cells for the Prophylaxis of Acute Graft-versus-Host Disease—A Phase II Study

Abstract EN

The efficacy and the safety of the administration of multipotent mesenchymal stromal cells (MMSCs) for acute graft-versus-host disease (aGVHD) prophylaxis following allogeneic hematopoietic cell transplantation (HSCT) were studied.

This prospective clinical trial was based on the random patient allocation to the following two groups receiving (1) standard GVHD prophylaxis and (2) standard GVHD prophylaxis combined with MMSCs infusion.

Bone marrow MMSCs from hematopoietic stem cell donors were cultured and administered to the recipients at doses of 0.9–1.3×106/kg when the blood counts indicated recovery.

aGVHD of stage II–IV developed in 38.9% and 5.3% of patients in group 1 and group 2, respectively, (P=0.002).

There were no differences in the graft rejection rates, chronic GVHD development, or infectious complications.

Overall mortality was 16.7% for patients in group 1 and 5.3% for patients in group 2.

The efficacy and the safety of MMSC administration for aGVHD prophylaxis were demonstrated in this study.